A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Schizophrenia
Interventions
DRUG

PF-03463275

30 mg Controlled Release tablet BID for 12 weeks

DRUG

Placebo

Placebo tablet BID

Trial Locations (37)

10304

Pfizer Investigational Site, Staten Island

10305

Pfizer Investigational Site, Staten Island

11366

Pfizer Investigational Site, Fresh Meadows

11423

Pfizer Investigational Site, Holliswood

19139

Pfizer Investigational Site, Philadelphia

20016

Pfizer Investigational Site, Washington D.C.

20036

Pfizer Investigational Site, Washington D.C.

30308

Pfizer Investigational Site, Atlanta

30328

Pfizer Investigational Site, Atlanta

30333

Pfizer Investigational Site, Decatur

30342

Pfizer Investigational Site, Atlanta

38119

Pfizer Investigational Site, Memphis

39232

Pfizer Investigational Site, Flowood

60068

Pfizer Investigational Site, Park Ridge

67207

Pfizer Investigational Site, Wichita

67211

Pfizer Investigational Site, Wichita

73034

Pfizer Investigational Site, Edmond

73116

Pfizer Investigational Site, Oklahoma City

77008

Pfizer Investigational Site, Houston

77401

Pfizer Investigational Site, Bellaire

78731

Pfizer Investigational Site, Austin

78754

Pfizer Investigational Site, Austin

89102

Pfizer Investigational Site, Las Vegas

89128

Pfizer Investigational Site, Las Vegas

90502

Pfizer Investigational Site, Torrance

90703

Pfizer Investigational Site, Cerritos

90723

Pfizer Investigational Site, Paramount

90805

Pfizer Investigational Site, Long Beach

90808

Pfizer Investigational Site, Long Beach

91436

Pfizer Investigational Site, Glendale

91910

Pfizer Investigational Site, Chula Vista

91950

Pfizer Investigational Site, National City

92025

Pfizer Investigational Site, Escondido

92845

Pfizer Investigational Site, Garden Grove

08078

Pfizer Investigational Site, Runnemede

08755

Pfizer Investigational Site, Toms River

08046

Pfizer Investigational Site, Willingboro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00977522 - A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia | Biotech Hunter | Biotech Hunter